# **Ohtuvayre (ensifentrine) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

### MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION		
MEDICATUN	DISPENSING INFORMATION	

MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
		THERAPY/REFILLS:		
<b>NEW THERAPY RENEWAL IF RENEWAL:</b> DATE THERAPY INITIATED:				
DURATION OF THERAPY (SPECIFIC DATES):				
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 2.1.2025 CAT009



# Ohtuvayre (ensifentrine) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?					
YES (if yes, complete below) MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	NO DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
<ul> <li>Chronic obstructive pulmonary d</li> <li>Other diagnosis:</li> </ul>					
3. REQUIRED CLINICAL INFORM. TO SUPPORT A PRIOR AUTHORI	ATION: PLEASE PROVIDE ALL REL ZATION.	LEVANT CLINICAL INFORMATION			
	in combination with a clinical trial	? 🗌 Yes 🔲 No			
Is patient a current or former cigarette smoker with a history of cigarette smoking ≥10 pack years? ☐ Yes ☐ No Please submit chart documentation. Does patient have a COPD Symptoms score of ≥2 on the Modified Medical Research Council (mMRC)					
Dyspnea Scale? Yes No Please submit chart documentation. Does patient have other respiratory disorders including, but not limited to, a current diagnosis of asthma, active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, interstitial lung diseases, unstable sleep apnea, known alpha-1 antitrypsin deficiency, core pulmonale, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary diseases? Yes No Please submit chart documentation.					
Has patient been using for at least 3 months some combination of 2 or 3 of the following: a long- acting beta-adenergic(LABA) with a long-acting muscarinic agent(LAMA) and/or an inhaled corticosteroid(ICS)? Yes No Please submit chart documentation.					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					
required information is received. <b>ATTESTATION:</b> I attest the inform understand that the Health Plan, ins	is are covered on all plans. This requ ation provided is true and accurate to surer, Medical Group or its designees cessary to verify the accuracy of the in	o the best of my knowledge. I s may perform a routine audit and			
©2017-2024 Prime Therapeutics Ma	nagement LLC, a Prime Therapeutics Commercial Clients. Revision Date: 2	s company			



CAT009

# **Ohtuvayre (ensifentrine) Prior Authorization Request Form** Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

## MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Prescriber Signature or Electronic I.D. Verification: Date:

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

> FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

